{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:10:27Z","timestamp":1772539827535,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.leukres.2020.106335","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T16:09:26Z","timestamp":1582560566000},"page":"106335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-2246","authenticated-orcid":false,"given":"Steven J.","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Bruyere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Hrynchak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Galbraith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulwahab J.","family":"Al Tourah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Dueck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Noble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled M.","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Sehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia L.","family":"Toze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2020.106335_bib0005","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106335_bib0010","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2020.106335_bib0015","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2020.106335_bib0020","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106335_bib0025","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106335_bib0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10428194.2011.605188","article-title":"Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials","volume":"53","author":"Gerrie","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2020.106335_bib0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106335_bib0040","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1200\/JCO.2013.49.6547","article-title":"Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study","volume":"32","author":"Hillmen","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106335_bib0045","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2020.106335_bib0050","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2020.106335_bib0055","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106335_bib0060","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2020.106335_bib0065","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2020.106335_bib0070","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"Suppl","key":"10.1016\/j.leukres.2020.106335_bib0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2019-126824","article-title":"Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): extended follow-up from the E1912 trial","volume":"134","author":"Shanafelt","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106335_bib0080","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","author":"Burger","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2020.106335_bib0085","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/bjh.14332","article-title":"Real-world clinical experience in the Connect\u00aechronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres","volume":"175","author":"Mato","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2020.106335_bib0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cncr.31738","article-title":"Real-world testing and treatment patterns in chronic lymphocytic leukemia: a SEER patterns of care analysis","volume":"125","author":"Seymour","year":"2019","journal-title":"Cancer"},{"issue":"114\u2013124","key":"10.1016\/j.leukres.2020.106335_bib0095","first-page":"e2","article-title":"Prognostic testing patterns and outcomes of chronic lymphocytic leukemia patients stratified by fluorescence in situ hybridization \/ cytogenetics : a real-world clinical experience in the connect CLL registry","volume":"18","author":"Mato","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2020.106335_bib0100","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1007\/s00277-019-03830-8","article-title":"Single-agent ibrutinib in RESONATE-2\u2122 and RESONATE\u2122 versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia","volume":"98","author":"Salles","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2020.106335_bib0105","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1002\/cam4.2268","article-title":"Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States","volume":"8","author":"Kabadi","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.leukres.2020.106335_bib0110","series-title":"Population estimates, B.C. Data Cat","author":"Government of British Columbia","year":"2018"},{"key":"10.1016\/j.leukres.2020.106335_bib0115","series-title":"Chronic Leukemia","author":"BC Cancer","year":"2012"},{"key":"10.1016\/j.leukres.2020.106335_bib0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.leukres.2017.01.023","article-title":"Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada","volume":"55","author":"Huang","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2020.106335_bib0125","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/bloodadvances.2017015396","article-title":"Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)","volume":"2","author":"Byrd","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2020.106335_bib0130","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cancergen.2014.08.006","article-title":"Population-based characterization of the genetic landscape of chronic lymphocytic leukemia patients referred for cytogenetic testing in British Columbia, Canada: the role of provincial laboratory standardization","volume":"207","author":"Gerrie","year":"2014","journal-title":"Cancer Genet."},{"key":"10.1016\/j.leukres.2020.106335_bib0135","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106335_bib0140","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/ejh.13040","article-title":"Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice","volume":"100","author":"Reiser","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2020.106335_bib0145","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-14-1889","article-title":"New strategies in chronic lymphocytic leukemia: shifting treatment paradigms","volume":"20","author":"Awan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2020.106335_bib0150","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/asheducation-2013.1.138","article-title":"Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies","volume":"2013","author":"Hallek","year":"2013","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.leukres.2020.106335_bib0155","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1517\/14656566.2014.891017","article-title":"New treatment options for chronic lymphocytic leukemia","volume":"15","author":"Delgado","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.leukres.2020.106335_bib0160","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood-2018-01-826008","article-title":"High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies","volume":"132","author":"Dreger","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106335_bib0165","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2020.106335_bib0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ejh.12678","article-title":"Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG)","volume":"96","author":"Cramer","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2020.106335_bib0175","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/bmt.2016.258","article-title":"Impact of drug development on the use of stem cell transplantation : a report by the European Society for Blood and Marrow Transplantation (EBMT)","volume":"52","author":"Passweg","year":"2017","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2020.106335_bib0180","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12185-013-1479-5","article-title":"Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies","volume":"99","author":"Davila","year":"2014","journal-title":"Int. J. Hematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:01Z","timestamp":1758934801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212620300400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":36,"alternative-id":["S0145212620300400"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106335","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106335"}}